AbbVie Announced Its 340B Rebate Pilot on October 2. Here’s What It Means for the Stock Before Vraylar’s 2027 Medicare Price Cut
AbbVie initiated a 340B Rebate Model Pilot for Vraylar, Linzess, and Imbruvica on October 2, ahead of Medicare's negotiated price cut for Vraylar in January 2027. This pilot aims to improve transparency and prevent duplicate discounts in the 340B drug pricing program, which requires drugmakers to offer discounts to safety-net healthcare providers. Despite potential pricing pressures, AbbVie's core business, driven by Skyrizi and Rinvoq, is expected to maintain revenue growth, with a mid-case target price suggesting a 38% total return by 2030.
BofA raises target for AbbVie stock to USD 289.00
BofA has increased its price target for AbbVie (ABBV) stock from $282.00 to $289.00, maintaining a Buy rating. This adjustment reflects confidence in AbbVie's long-term growth driven by acquisitions and investments in immunology and neuroscience, despite pressures on older products. The company reported strong Q2 2026 revenue and is set to release Q3 2026 results on October 30, 2026.
How Investors Are Reacting To Regeneron Pharmaceuticals (REGN) Sanofi Alliance Expansion
Regeneron Pharmaceuticals announced early data for two new therapies and an expanded alliance with Sanofi, potentially adding up to US$8 billion in milestones. This expansion aims to diversify Regeneron's revenue beyond its current blockbusters and deepen its immunology pipeline. Investors are evaluating how this collaboration and new drug data will influence the company's long-term growth and address pressure on its existing EYLEA franchise.
AbbVie declares a quarterly dividend as AbbVie stock trades flat at EUR 233.55
AbbVie Inc. has declared a quarterly cash dividend of USD 1.73 per share, payable on November 16, 2026, to stockholders of record on October 15, 2026. The company's stock is currently trading flat at EUR 233.55 in weekend trading at Lang & Schwarz, unchanged from its previous close. This dividend announcement comes as the stock maintains a stable price point.
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
This article compares AbbVie (ABBV) and Bristol Myers (BMY), two pharmaceutical companies that have recently navigated or are about to navigate patent expirations. While AbbVie successfully replaced its blockbuster drug Humira with Skyrizi and Rinvoq, showing strong growth and operating margins, Bristol Myers is highlighted as a cheaper stock with better net margins and return on equity, despite facing its own upcoming patent cliff. The analysis concludes that AbbVie is the better business, but Bristol Myers is the better-priced stock, offering a higher yield and lower forward multiple.
Genmab A/S reports 45.9% Rina‑S response in ovarian cancer trial
Genmab A/S announced a 45.9% confirmed tumor response rate for its ovarian cancer drug Rina-S, with responses lasting a median of 12.1 months in a Phase 1/2 study involving 109 patients. While the single-arm study shows promising activity across various folate receptor alpha expression levels, it lacks a control arm for direct comparison to chemotherapy. The company's Phase 3 RAINFOL-02 trial is ongoing, and its next financial report in November will provide further insight into development costs.
AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
AbbVie recently received FDA approval for Juvmo (tavapadon), a new once-daily Parkinson's pill. This approval is significant as Juvmo is a key asset from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, designed to strengthen its neuroscience pipeline. The drug offers a new treatment option for Parkinson's patients by selectively activating D1/D5 dopamine receptors and is expected to contribute to AbbVie's growing neuroscience portfolio, with projected annual sales of $1.4 billion by 2040.
Merck & Co., Inc. (MRK) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Merck & Co., Inc. (MRK) stock, including its current price, recent news, and historical performance data. It highlights the stock's performance against the S&P 500, showing significant year-to-date and one-year returns, and lists various news articles related to Merck's drug trials and market performance. The page also includes details on trading activity, including overnight sessions.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a U.S. government pilot program starting January 1, 2027, to test a new rebate system for discounted medicines under the 340B program. This initiative aims to improve pricing transparency and prevent duplicate discounts for drugs like Imbruvica, Linzess, and Vraylar, especially as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also approved for this federal pilot.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a US government pilot program to test a new rebate system for discounted medicines under the 340B program, starting January 1, 2027. This initiative aims to improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also part of this federal pilot.
How to Create a Million-Dollar Stock Portfolio
This article discusses strategies for building a million-dollar stock portfolio, drawing lessons from successful non-professional investors like Ronald Read, Anne Scheiber, and Grace Groner. These investors achieved significant wealth by investing for decades, rarely selling, and reinvesting dividends in blue-chip companies. The article highlights three specific stocks—Wells Fargo (WFC), Abbott Laboratories (ABT), and AbbVie Inc. (ABBV)—as examples of long-term investment opportunities, emphasizing their dividend yields and growth potential.
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie (ABBV) has received FDA approval for Juvmo, a new once-daily oral treatment for Parkinson's disease, with a commercial launch planned for October 2026. This drug, the first selective D1/D5 dopamine receptor agonist, is expected to significantly boost AbbVie's neuroscience franchise, which already includes Vyalev and Duopa, aiming for over $5 billion in peak sales from these therapies. The approval also validates AbbVie's 2024 acquisition of Cerevel Therapeutics, despite previous setbacks with other assets from the deal.
C4 Therapeutics Inc (CCCC-Q) Stock Price and News
This article provides stock information and recent news for C4 Therapeutics Inc. (CCCC-Q), a biopharmaceutical company focused on developing therapies for cancer and neurodegenerative conditions. The news section highlights recent reports on their cemsidomide myeloma data, analyst ratings, financial results, and collaborations with Roche.
Cytomx Thera (CTMX-Q) Stock Price and News
This article provides stock information and recent news for Cytomx Therapeutics (CTMX-Q), an oncology-focused biopharmaceutical company. It lists various news headlines from September 2026 back to May 2026, highlighting analyst opinions, corporate updates like board appointments and partnerships, and earnings call summaries. The company specializes in developing Probody™ therapeutics for cancer treatment, with a focus on precision cancer immunotherapy and Probody drug conjugates.
AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY), highlighting the dilemma investors face between AbbVie's growth premium and Bristol Myers' perceived value trap. AbbVie shows strong revenue growth driven by immunology but has a high valuation, while Bristol Myers Squibb, despite a lower valuation, faces legal challenges and patent expiry risks. The article examines their financial profiles, risks, and outlooks for 2026, suggesting AbbVie is a better long-term investment even at a premium.
RBC Capital Remains a Hold on Novartis AG (NOVN)
RBC Capital analyst Trung Huynh has maintained a Hold rating on Novartis AG (NOVN) with a price target of CHF120.00. This aligns with the Street's general consensus, suggesting a Hold rating for Novartis AG with an average price target of CHF124.92. The company recently reported quarterly revenues of CHF14.16 billion and a net profit of CHF3.21 billion for the quarter ending June 30.
LQDT: Liquidity Services Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Liquidity Services Inc. (LQDT), including its current stock price, market capitalization, and business segments. It highlights recent bullish sentiment for LQDT due to a flat-base consolidation breakout and strong buy recommendations from Zacks, attributing its success to off-loading excess inventory for major retailers and government entities. The company's financials, such as EPS and revenue per employee, are also detailed.
Regeneron (REGN) Stock May Be Underpriced Despite Its $1b Alliance Expansion
Regeneron Pharmaceuticals (REGN) stock appears potentially undervalued, trading at a P/E ratio close to its sector average but below its peer group, according to Simply Wall St. This assessment comes despite a recent expansion of its alliance with Sanofi, which brings a US$1 billion upfront payment and potential milestone payments. The analysis suggests that Regeneron's current earnings multiple is at a discount to what a Fair Ratio benchmark indicates, factoring in the company's margins, growth profile, size, and risk.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY) as investment options for 2026, highlighting their financial profiles, growth drivers, and risk factors. AbbVie is seen as a higher-growth stock with new immunology drugs, while Bristol Myers Squibb offers a significant valuation discount but faces litigation and patent expiration challenges. The author recommends AbbVie for long-term investors despite its higher price, anticipating strong growth in net income.
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
This article compares Johnson & Johnson (JNJ) and Eli Lilly (LLY) as investment options for 2026, highlighting their different approaches to the pharmaceutical market. JNJ offers diversified stability through drugs and medical devices, while LLY provides rapid growth driven by blockbuster treatments for diabetes and obesity. The analysis delves into each company's financial performance, risk profiles, and valuation metrics, concluding that Eli Lilly's high growth potential, despite its premium valuation, makes it a more compelling choice for long-term investors.
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 3,937,500 shares in its initial public offering at $17.00 per share, increasing the total shares sold to 30,187,500 and gross proceeds to approximately $513.2 million. Including a concurrent private placement with AbbVie, the aggregate gross proceeds reached approximately $602.5 million. The company, a late-stage clinical biotechnology firm, focuses on developing next-generation siRNA therapeutics for various diseases.
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 3,937,500 shares of its common stock at $17.00 per share, closing on October 1, 2026. This brings the total shares sold in the IPO to 30,187,500, raising approximately $513.2 million in gross proceeds. Including a concurrent private placement with AbbVie, ADARx's total gross proceeds from the offering and private placement amounted to approximately $602.5 million.
AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Highlights Dividend Concerns
AbbVie (NYSE: ABBV) announced positive phase 3 trial results for Rinvoq in treating non-segmental vitiligo, showing sustained repigmentation. While this strengthens AbbVie's immunology portfolio, the article raises concerns about the sustainability of its dividend due to a high payout ratio of 85% and the stock being modestly overvalued by 17.7%. Insider selling and mixed guru activity further suggest caution for dividend-focused investors.
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
ADARx Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 3,937,500 shares of its common stock at $17.00 per share, bringing the total shares sold in its IPO to 30,187,500 and gross proceeds to approximately $513.2 million. Including a concurrent private placement with AbbVie, the aggregate gross proceeds reached about $602.5 million. The company is a late-stage clinical biotechnology firm focused on developing next-generation siRNA therapeutics for various diseases.
AbbVie Presents Long-Term RINVOQ® Data Showing Continued Repigmentation in Non-Segmental Vitiligo
AbbVie announced positive long-term data from its Phase 3 Viti-Up-1 and Viti-Up-2 studies for RINVOQ® (upadacitinib) in non-segmental vitiligo, showing continued facial and total body repigmentation through week 76. The results also indicated numerically higher responses when RINVOQ was combined with narrowband ultraviolet B (NB-UVB) phototherapy. These findings support RINVOQ as a systemic treatment option and open avenues for further research into combination therapies for vitiligo patients.
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent
Sanofi and Regeneron have expanded their R&D alliance, with Sanofi investing $1 billion to develop four next-generation antibody drugs intended to succeed their blockbuster immunology drug, Dupixent. These new therapies, stemming from the same Regeneron platform that produced Dupixent, are projected to reach pivotal testing around 2029, strategically timed before Dupixent's patent expiration in 2031. The agreement also settles prior litigation between the companies regarding Dupixent's commercialization.
AbbVie to Host Third-Quarter 2026 Earnings Conference Call
AbbVie (NYSE: ABBV) is scheduled to announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. The company will host a live webcast of the earnings conference call at 8 a.m. Central time, accessible via its Investor Relations website. An archived version of the webcast will be available later the same day.
AbbVie to Host Third-Quarter 2026 Earnings Conference Call
AbbVie (ABBV) announced it will host a conference call to discuss its third-quarter 2026 earnings. The announcement was made via PR Newswire. This news item is a headline-only release with no further details provided in the body.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
This article examines AbbVie Inc. (ABBV), a trending stock, by analyzing its earnings estimate revisions, revenue growth forecasts, and valuation. It highlights that the company has a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market in the near term. The analysis provides key financial data and explains why these factors are important for investment decisions.
There’s one pharma-linked stock most investors have never heard of. It’s on Josh Brown’s list
Josh Brown and Sean Russo highlight West Pharmaceutical Services (WST) as a key player in the pharmaceutical industry that most investors overlook. West Pharmaceutical manufactures essential components for injectable drugs, benefiting from the growth of biologics, vaccines, insulin, and GLP-1 weight loss drugs. Despite a past downturn, the company's fundamentals are recovering strongly, driven by increased demand for high-value components and effective management changes, positioning it for potential further gains.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
This article examines AbbVie Inc. (ABBV), a trending stock on Zacks.com, by analyzing key factors like earnings estimate revisions, revenue growth forecasts, and valuation. It highlights that AbbVie's stock has seen a -0.1% return over the past month, with positive earnings growth projections for the current and next fiscal year. The company holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the broader market in the near term.
AbbVie long-term data buoys Rinvoq for vitiligo
AbbVie's drug Rinvoq (upadacitinib) has shown continued effectiveness in long-term data for patients with non-segmental vitiligo. Phase 3 studies, specifically the Viti-Up-1 study, reported increased facial and total body repigmentation through week 76. At week 76, 55.1% of patients achieved significant repigmentation.
B.Riley reiterates Kymera Therapeutics stock rating on new trial data
B.Riley has reiterated a Buy rating and a $155.00 price target for Kymera Therapeutics (NASDAQ: KYMR) after the company presented new data from its oral STAT6 degrader KT-621 at EADV’26. The stock has seen a 104% increase over the past year, reflecting strong investor interest. Several other analysts, including Stifel, BofA Securities, Guggenheim, and Piper Sandler, have also recently increased their price targets and maintained Buy or Overweight ratings, indicating broad positive sentiment driven by potential Phase 2b data for KT-621.
JPMorgan initiates Spyre stock with Overweight on IBD pipeline By Investing.com
JPMorgan has initiated coverage on Spyre Therapeutics Inc. (NASDAQ:SYRE) with an Overweight rating and a $110 price target, citing the company's strong inflammatory bowel disease (IBD) pipeline. Spyre's stock has seen a significant 441% gain over the past year, with JPMorgan projecting substantial upside potential, particularly from its combination therapies set to deliver Phase 2 readouts in 2027. The firm believes Spyre could capture a low-teens percentage share of the U.S. advanced biologics IBD market by the 2040s, leading to annual worldwide sales of $6 billion to $7 billion.
AbbVie Stock: Buy, Sell, or Hold in October?
AbbVie, a pharmaceutical giant and Dividend King, has successfully navigated the patent cliff of its blockbuster drug Humira by launching new immunology drugs Skyrizi and Rinvoq and acquiring companies like Allergan. Analysts predict significant revenue and EPS growth for AbbVie between 2025 and 2028, driven by these new drugs and recent acquisitions. Despite a turbulent market, the article suggests holding rather than selling AbbVie stock, citing its reasonable valuation and decent forward yield.
Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?
Amgen (AMGN) has reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, leading to a significant increase in its share price. Despite this, some analyses suggest the stock is overvalued due to challenges in the obesity market, regulatory hurdles, and erosion of legacy drug sales. Conversely, Simply Wall St's DCF model indicates Amgen might be undervalued based on future cash flow estimates, highlighting a split in expert opinion regarding the company's true worth.
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates
AbbVie announced positive clinical trial results for two pipeline candidates: zumilokibart for moderate to severe atopic dermatitis and ABBV-295 for weight loss. Zumilokibart, an eczema treatment, showed statistically significant improvements in skin clearance and itch reduction in a Phase 2 study. The novel amylin analog ABBV-295 demonstrated dose-dependent body weight reductions in a Phase 1 trial, with a favorable safety profile.
Eaton, AMD and SpaceX: CNBC ‘Final Trades’ - Advanced Micro Devices (NASDAQ:AMD)
CNBC's "Final Trades" segment featured several analyst recommendations. Joseph M. Terranova picked Eaton Corporation plc (NYSE: ETN), citing a recent Overweight rating from Wells Fargo. Stephanie Link highlighted Space Exploration Technologies Corp. (NASDAQ: SPCX) after its Starship rocket reached orbit, while Jason Snipe named AbbVie Inc. (NYSE: ABBV) following FDA approval for its Parkinson's drug. Joshua Brown recommended Advanced Micro Devices, Inc. (NASDAQ: AMD) based on a reiterated Buy rating from StoneX.
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
BofA has raised price targets for both AbbVie (ABBV) and Johnson & Johnson (JNJ), indicating stronger conviction in AbbVie due to its valuation and pipeline. AbbVie's Q2 revenue increased by 10%, driven by Skyrizi and Rinvoq, while J&J also saw operational growth. Both companies are navigating patent losses and have upcoming catalysts, with AbbVie trading at a lower forward earnings multiple than J&J.
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
Bank of America has raised price targets for both AbbVie (ABBV) and Johnson & Johnson (JNJ), indicating confidence in their growth despite upcoming patent cliffs. BofA maintains a stronger conviction in AbbVie, upgrading it to a Buy rating with a $289 target, citing its favorable patent timeline, strong Q2 revenue growth, and strategic acquisitions like Apogee. Johnson & Johnson received a Neutral rating with a $278 target, reflecting some optimism already priced into the stock.
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1
AbbVie presented detailed Phase 1 data for its investigational long-acting amylin analog, ABBV-295, for obesity. The study showed least-squares mean body weight reductions ranging from -7.8% to -9.8% at Week 12 for the once-weekly dosing cohorts. This indicates promising early results for ABBV-295 as a potential treatment for obesity.
Top 10: Bio-Pharmaceutical Companies
Healthcare Digital has compiled a ranking of the top 10 bio-pharmaceutical companies based on the size of their R&D pipelines, utilizing data from Citeline’s 2026 Pharma R&D Annual Review. The article highlights the extensive drug development efforts of these leading firms, ranging from established industry giants like AstraZeneca and Roche to growing players such as Jiangsu Hengrui Pharmaceuticals, showcasing their contributions to shaping the future of medicine. Each company's profile includes details on their R&D pipeline size, number of employees, key therapeutic areas, and strategic acquisitions, illustrating their impact on the global biopharmaceutical landscape.
FEIG ETF Holdings List — HAN:FEIG
This article provides a detailed list of the ETF holdings for FEIG (Fidelity EUR Corp Bond Research Enhanced PAB UCITS ETF) as of October 2, 2026. It includes the symbol, weight percentage, number of shares, and market value for each holding. Key holdings mentioned include Euro, JCDecaux SE, Pandora A/S, Mastercard Incorporated, and Stryker Corporation.
AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis
AbbVie announced positive Phase 2 data for its investigational drug zumilokibart, an anti-IL-13 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis. All three dose regimens of zumilokibart met the primary endpoint compared to placebo, demonstrating its efficacy in this patient population.
At 16 weeks, all three doses of AbbVie’s eczema treatment improved skin more than placebo.
AbbVie announced positive results from its Phase 2 APEX Part B study of zumilokibart for moderate to severe atopic dermatitis, with all three dose regimens meeting the primary endpoint of significantly improved EASI-75 response rates compared to placebo at Week 16. The mid-dose regimen was selected for Phase 3 development to evaluate extended dosing intervals. The drug also showed significant improvements in skin clearance and itch, with common adverse events including nasopharyngitis, headache, and noninfective conjunctivitis.
AbbVie Inc (ABBV) Stock Down 1.1% but Still Overvalued -- GF Sco
AbbVie Inc (ABBV) shares experienced a 1.1% decline but remain overvalued according to GuruFocus' GF Value, trading 19.0% above its intrinsic value estimate. The company holds a GF Score of 77/100, indicating above-average performance, particularly in profitability, but concerns exist regarding its financial strength and momentum. Insider selling further signals potential overvaluation or strategic concerns, advising caution for investors.
Enterprise value of AbbVie, Inc. – HAN:4AB
This article focuses on the enterprise value of AbbVie, Inc., traded on the Hannover Stock Exchange under the ticker 4AB. It appears to be a stub or a placeholder, as no specific financial data or detailed analysis is presented, only the title and navigation elements from a financial platform.
If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
This article examines the hypothetical growth of a $1000 investment in AbbVie (NYSE: ABBV) stock over the past 10 years. An initial $1000 investment would now be worth $4,164.00, due to an average annual return of 15.37%, outperforming the market by 1.84% annually. The piece highlights the significant impact of compounded returns on wealth growth over time.
What Is Regeneron Pharmaceuticals (REGN) Facing After A Rival Matched Its Key Eye Drug?
Kodiak Sciences recently announced Phase 3 data for its eye drug Zenkuda, showing it matched Regeneron Pharmaceuticals' Eylea in treating macular degeneration, with the added benefit of less frequent dosing (twice a year versus Eylea's typical every eight weeks). This development puts pressure on Regeneron's Eylea franchise, highlighting the need for diversification and the importance of its broader pipeline beyond this key eye drug. Regeneron's strategy involves leveraging durable cash flows from core franchises to fund a wide pipeline, with new assets like Eylea HD and other immunology and oncology programs aimed at reducing reliance on a single product.
AbbVie Inc. Stock Grades | ABBV
This Barron's article provides a detailed stock grade and financial overview for AbbVie Inc. (ABBV). It includes analyst ratings with an average price target of $280.00, key financial metrics such as EPS, P/E ratio, and dividend yield, along with company information and peer comparisons. The article also outlines data sources and disclaimers for the financial information presented.
